 WATERTOWN, Mass., Sept. 21, 2021 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Companys Management will participate in a fireside chat and one-on-one investor meetings at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021. 